-
11.01.2022 | A strong pipeline of vaccines is under development with nearly 8 different vaccines targeting the critical priority pathogens of AMR
BioSpectrum | Dr Renu Swarup, with almost three decades in the DBT, brings a wealth of knowledge and experience to support ICARS in its mission to combat antimicrobial resistance (AMR) in low- and middle-income countries (LMICs).
-
11.01.2022 | Is AMR Modern-day Frankenstein’s Monster?
Biospectrum | Antimicrobial Resistance (AMR) continues to pose a significant public health problem in terms of mortality and economic loss.
-
10.28.2022 | Unhealthy Antibiotics
PHPod | Kevin Outterson works to improve access to antibiotics and address drug-resistant bacteria. He is the executive director of CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) and a Boston University College of Law professor. Listen his PHPod conversation with Connor McCombs and Bethany Hallenborg. -
10.20.2022 | Day Zero Diagnostics Secures Additional $8.2M From CARB-X
GenomeWeb | NEW YORK – Day Zero Diagnostics said on Thursday that it has been granted an additional $8.2 million in funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, a global nonprofit organization.
-
10.18.2022 | Addressing the Next Pandemic in India
Kashmir Observer | AS India struggles with the growing Omicron wave of COVID-19, another pandemic is gathering force that could someday be equally lethal. While India — and the rest of the world — was caught flat-footed by COVID-19, there is still time to prepare for this looming public health threat, if political and healthcare leaders act now.
-
10.17.2022 | Gunnar Esiason’s odyssey through cystic fibrosis and the American health care system.
BC Magazine | “I can’t impress upon everyone enough the fear that you hold when you’re on your last antibiotic.”
-
10.14.2022 | Symposium focuses on crisis of drug-resistant infections
Brighter World | While researchers work to develop new antibiotics for drug-resistant infections, world-leading experts say the crisis of antimicrobial resistance (AMR) won’t be solved by new drugs alone.
-
10.13.2022 | From pandemics to prevention: our vision for Infectious Disease
Wellcome | Gordan Dougan, Director of Infectious Disease at Wellcome, outlines our aspirations for a world where infectious diseases are under control.
-
10.12.2022 | CARB-X’s call for proposals seeks to fill gaps in the global AMR pipeline
Bio | The global nonprofit partnership CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) which is focused on supporting antibacterial research, last week opened a call for proposals addressing vital antimicrobial resistance (AMR) challenges.
-
10.06.2022 | Her antibiotic company failed. Now she’s helping others avoid the same fate.
PharmaVoice | The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.
-
10.05.2022 | CARB-X notes new funding rounds to address superbugs
CIDRAP | The public-private partnership that’s been leading efforts to boost early-stage antibiotic development announced new funding rounds this week.
-
10.04.2022 | Superbug killers wanted – Hurdles in the race to develop new antibiotics
One Health Trust | Two centuries ago, people could die from a simple scratch. It was the pre-antibiotic era when infections killed babies within hours, a cold could turn deadly within days, and people survived injuries through luck alone.
-
09.20.2022 | STD Experts Say US Faces Out of Control Syphilis and Gonorrhea Crisis
The Science Times | STD experts issued a warning this week about a crisis in sexually transmitted diseases. At the biannual STD Prevention Conference, David Harvey, the executive director of the National Coalition of STD Directors, described the situation as out of control.
-
09.13.2022 | The five hottest private biotech companies in India
Labiotech | India is brimming with biotech companies and a young and skilled workforce. Here’s a quick glance at the private healthcare biotechs in India that captured investors’ imaginations in the last couple of years.
-
09.13.2022 | The superbugs are coming — oh wait, they’re here.
Politico | The CDC estimates 35,000 people die each year in the U.S. from drug-resistant infections.
-
09.13.2022 | Getting a Grip on How to #SquashSuperbugs
Infectious Conversations | As we continue to encourage urgency and action on the problem of antimicrobial resistance, the Partnership to Fight Infectious Disease (PFID) is convening discussions among health care professionals, policy experts and others to help underscore the threat AMR poses as “the next pandemic,” the need to address it now, and how we can build on lessons learned throughout the COVID-19 pandemic and other experiences.
-
09.02.2022 | Neglect this silent pandemic at your peril
Politico | Antimicrobial resistance is a ‘threat to humanity’ that will lead to drug-resistant superbugs.
-
09.01.2022 | Avails Medical Awarded Additional $1.7M in CARB-X Funding
360Dx | Avails Medical announced on Thursday that it has been awarded an additional $1.7M in CARB-X Funding
-
08.21.2022 | Should I Be Worried About Resistance to Antibiotics
Bloomberg | The World Health Organization calls resistance to antibiotics “one of the biggest threats to global health, food security and development today.”
-
08.16.2022 | INCATE: a partnership to boost the antibiotic pipeline
Nature Reviews | INCATE, the INCubator for Antibacterial Therapies in Europe, aims to boost the antibiotic pipeline by accelerating the translation of academic innovation into industrial R&D projects to tackle antimicrobial resistance. Founded in 2021 as a partnership of research institutions and pharma companies, INCATE provides advice, community and non-dilutive funding to start-up companies.
-
07.29.2022 | CARB-X: Accelerating Global Antibacterial Innovation to Combat Resistance
The MTPConnect Podcast | On a visit to Australia, CARB-X Chief Scientific Officer Dr Richard Alm (originally from Adelaide) joins the podcast to discuss the threat of antimicrobial resistance, the need to take a ‘village approach’ to develop new life-saving antimicrobial treatments, why it’s time for an AMR accelerator in Australia and tips for Australian start-ups & researchers on applying for future CARB-X funding rounds!
-
07.15.2022 | Antibiotic-resistant infections could dwarf COVID-19 pandemic
Boston Globe | These life-saving drugs are being taken for granted and many bacteria have become resistant to them.
-
07.15.2022 | As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger
Kaiser Health | Forget covid-19, monkeypox, and other viruses for the moment and consider another threat troubling infectious disease specialists: common urinary tract infections, or UTIs, that lead to emergency room visits and even hospitalizations because of the failure of oral antibiotics.
-
07.14.2022 | Major Layoffs Underscore Continuing Struggle to Develop New Antibiotics
PEW | Economic incentives could help sustain efforts to bring new and effective drugs to market
-
07.14.2022 | How the pandemic screwed up our antibiotics
Vox | Antibiotic resistance was already a crisis. Covid-19 made it an emergency.
-
07.12.2022 | WHO Issues Urgent Call to Develop New Vaccines to Tackle Drug-Resistant Bacteria
Health Policy Watch | With antimicrobial resistance (AMR) on the rise globally, the World Health Organization (WHO) Tuesday issued an urgent call to step up investment and research into vaccine candidates that can tackle the problem of drug-resistant bacteria in a new report that looks at key research gaps and opportunities.
-
06.30.2022 | Addressing Antimicrobial Resistance
ASPR BLOG | Dawn O’Connell, HHS Assistant Secretary for Preparedness and Response, discusses the next phase of the partnership with CARB-X to address antimicrobial resistance. “There is no single solution to address the threat of antimicrobial resistance, but our global partnership to build an innovative, diverse array of pre-clinical and early clinical products is making meaningful progress. I look forward to seeing the investments that we make today in time, funding, and expertise translate into a portfolio of tools that save lives in future disasters.”
-
06.23.2022 | SpeeDx RNA/DNA Ratio Method Shows Promise for Bacterial Viability, Susceptibility Testing
GENOMEWEB | SpeeDx has created a phenotypic test, based on the RNA/DNA ratio of a diagnostic target gene, to determine viability and antimicrobial susceptibility of bacteria. SpeeDx intends to debut the technology, branded InSignia™, as part of a lab-based gonorrhea susceptibility test and ultimately to incorporate it into a CARB-X-funded point-of-care testing platform that it is codeveloping with QuantumDx.
-
06.15.2022 | UK to Roll Out Drugs From Pfizer, Shionogi to Fight Superbugs
Bloomberg | England is rolling out a pair of antibiotics from Pfizer Inc. and Shionogi & Co. as part of a pioneering program aimed at stimulating a broken market and taking on the rising threat of superbugs.
-
06.13.2022 | Fighting Superbugs: How an Indian Avenger is building a life-saving weapon
FORBES INDIA | Big pharma has little interest in antibiotics because there’s not enough money in it, making Bugworks, with its R&D in India, among a handful of startups that is attempting the impossible.
-
06.10.2022 | HHS Promises up to $300 Million Over 10 Years to Fight Antibiotic-Resistant Bacteria
Healtcare Weekly | The U.S. Department of Health and Human Services (HHS) announced it will commit $20 million this year and can provide up to $300 million over the next 10 years to fight antimicrobial resistant (AMR) infections through the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
-
06.01.2022 | Boosting innovation in antibacterials: Pitfalls and potential solutions
BioPharma Reporter | A well-funded and appropriately rewarded biotech ecosystem is needed for the next generation of antibacterials to reach the clinic and beyond, according to BIO’s State of Innovation in Antibacterial Therapeutics report
-
05.26.2022 | Inside Locus Biosciences’ $35M funding: What it means for gene editing startup in RTP
WRAL |Gene editing startup Locus Biosciences is another step closer to actualizing its biotherapeutics against bacterial diseases after landing $35 million in additional capital.
-
05.25.2022 | Antibiotic Resistance Could Be a Top Cause of Death by 2050, Experts Say – Can targeted investments rebuild the antibiotic pipeline?
MEDPAGE TODAY | A global coalition is necessary to ensure countries around the world benefit from the antibiotics that result from current innovations.
-
05.24.2022 | HHS to invest up to $300M over next 10 years into CARB-X efforts to combat antimicrobial resistant infections
HOMELAND PREPAREDNESS NEWS | Beginning with $20 million this year, the United States Department of Health and Human Services (HHS) will commit up to $300 million to support antimicrobial resistant (AMR) infection research conducted through the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) over the next decade.
-
05.23.2022 | A Better Way to Fund the Fight Against Superbugs
BLOOMBERG | As bacteria become increasingly resistant to antibiotics, the pipeline of drugs to counter so-called superbugs has virtually dried up. Three years after announcing a strategy to boost investment in antibiotics, England is poised to fund a pair of new drugs by offering companies a fixed annual fee regardless of how much—or how little—they’re used.
-
05.20.2022 | The Battle Against Bugs
BOSTON BUSINESS JOURNAL | As the threat posed by drug-resistant bacteria continues to grow, the companies striving to develop antibiotics remain notoriously underfunded.
-
05.19.2022 | Battle Against Antibiotic-Resistant Bacteria Gets HHS Cash Boost
BLOOMBERG LAW | The Department of Health and Human Services will commit $20 million this year and has options to provide up to $300 million over the next 10 years to combat antimicrobial resistant (AMR) infections, according to the agency Thursday.
-
05.19.2022 | HHS, Wellcome Commit $370M in New Funding for CARB-X
360DX | CARB-X will receive up to an additional $370 million from the US Department of Health and Human Services and charitable foundation Wellcome to continue funding drug-resistant bacteria research, including the development of diagnostics.
-
05.19.2022 | CARB-X receives new round of funding from BARDA, Wellcome
CIDRAP | The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced renewed funding from the US government’s Biomedical Advanced Research and Development Authority (BARDA) and UK charitable foundation Wellcome.
-
05.19.2022 | Antibiotic resistance efforts get a boost as CARB-X gets $370M
BOSTON BUSINESS JOURNAL | Kevin Outterson has spent the better part of the last year in conversations with CARB-X’s previous backers. Now, those efforts have yielded fruit: The organization has another $370 million to invest in research targeting drug-resistant bacteria.
-
05.19.2022 | Can We Prevent Antibiotic Resistance?
THE BRINK | Antibiotics are losing effectiveness—and millions are dying as a result. CARB-X, a BU-based partnership that aims to solve antimicrobial resistance, has been given up to $370 million in new funding from the US government and charitable foundation Wellcome
-
05.19.2022 | HHS commits $300M to global accelerator targeting antibiotic-resistant bacteria
FIERCE | The Department of Health and Human Services announced Thursday morning a $300 million commitment to supporting a public-private antibiotic-resistant bacteria accelerator over the next decade.
-
05.12.2022 | Are Antibiotics Doomed? David Hyun & Erin Duffy on the Crisis No One Talks About
FREE FORUM PODCAST | In 2019, about 1.27M people died directly due to antimicrobial resistance – significantly more than from Covid in two years. When we lose antibiotics, we will be in a different world. Joint and organ replacement, cancer treatments and many other medical procedures will be a thing of the past. Terrence McNally talks about the growing dangers of antibiotic resistance and the lack of new drugs with David Hyun, MD, who directs the Antibiotic Resistance Project at the Pew Charitable Trust, and Erin Duffy, Chief of R&D at CARB-X.
-
05.11.2022 | The antimicrobial pipeline is ‘dry’ and that’s a problem
PHARMAPHORUM | Antimicrobial resistance is a growing problem and one that is already claiming over a million lives per year. The situation is urgent but finding a sustainable solution is a difficult prospect.
-
04.27.2022 | ENTASIS THERAPEUTICS HOLDINGS INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations
MARKET SCREENER | The report includes a discussion and analysis of Entasis’ financial condition and results of operations.
-
04.25.2022 | UK takes subscription approach for new antibiotics
CHEMISTRY WORLD | The UK has adopted the world’s first subscription payment model for two new antibiotics. The National Health Service will pay Pfizer and Shionogi up to £10 million a year for ten years for them, regardless of how many doses are administered to patients.
-
04.20.2022 | SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
BENZIGA | SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic.
-
04.20.2022 | Clinical update: SNIPR BIOME doses first human subjects with CRISPR-based antibiotic
CRISPR MEDICINE NEWS | SNIPR BIOME announced this morning that it has dosed the first participants in a clinical trial for SNIPR0001, an orally administered CRISPR-based therapeutic designed to reduce E. coli colonization in the gut to prevent blood infections in patients with cancer.
-
04.18.2022 | An episode about CARB-X with Erin Duffy and Kevin Outterson
PROGRESS, POTENTIAL & POSSIBILITIES PODCAST | Host Ira Pastor speaks with Erin Duffy and Kevin Outterson about how and why CARB-X supports innovative antibiotics vaccines and diagnostics to treat, prevent and diagnose AMR bacterial infections for a global population.
-
04.13.2022 | Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
BAKERSFIELD | Vedanta Biosciences, a leading clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication in the journal Cell Host & Microbe of the results from a Phase 1a/1b study evaluating the safety, tolerability, and colonization dynamics of VE303 in healthy adults. VE303 is a potential first-in-class defined bacterial consortium candidate for the prevention of recurrent Clostridium difficile infection (CDI). The company will also share three research updates across its VE303 and VE202 (for inflammatory bowel disease) programs in podium presentations at Digestive Disease Week in May 2022.
-
04.11.2022 | Day Zero Diagnostics Announces the Launch of Day Zero Lab Services
CISION PRWEB | Day Zero Diagnostics, Inc., an infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced the launch of Day Zero Lab Services focused on providing hospitals with services focused on whole-genome sequencing-based assays.
-
04.07.2022 | Lumen Bioscience: Spirulina-based platform enables rapid, low-cost development of oral biologics
BIOPHARMA-REPORTER | Researchers at Lumen Bioscience report in Nature Biotechnology genetic engineering methods to highly express bioactive proteins in spirulina using large-scale cultivation and processing methods appropriate for biopharmaceutical manufacturing.
-
04.05.2022 | Boston University Led CARB-X Grants Clarametyx Biosciences an Additional $3.89 Million in Funding to Accelerate Anti-Biofilm Therapy for Bacterial Infections TrialSite Staff April 5, 2022
TrialSite News | Clarametyx Biosciences, a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilm, announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), has awarded the company an additional $3.89 million in option funding. The grant will be used toward advancing the development of CMTX-101, a novel anti-biofilm therapy with a first targeted indication for moderate-to-severe pneumonia.
-
04.04.2022 | Pharma’s ambitious new antibiotic venture fund makes its first investments
STAT | The AMR Action Fund is providing an undisclosed portion of its $1 billion in initial backing — much of which comes from several of the world’s largest drug manufacturers — toward Venatorx Pharmaceuticals and Adaptive Phage Therapeutics. The two privately held companies are taking a different approach toward developing therapies that can fight drug-resistant infections.
-
04.04.2022 | Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund
HERALD CHRONICLE | Venatorx Pharmaceuticals, Inc., a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, today announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.
-
03.24.2022 | Integrated Biotherapeutics Awarded $3.55M Grant to Study Immune Correlates of Protection Against Recurrent Staphylococcal Infection
WFMZ | Study is expected to provide insights into mechanisms of protection against staph infection. IBT and its subsidiary Integrated BioTherapeutic Vaccines (IBV) are developing IBT-V02, a novel vaccine for S. aureus infections with support from CARB-X and Novo Holdings. IBT-V02 will enter Phase 1 clinical trial this year.
-
03.21.2022 | Superfood spirulina harnessed as biomanufacturing engine
HEALTH TECH WORLD | A common food source has been converted into a biomanufacturing platform that enables mass production of biologic drugs for common diseases that currently lack effective treatments. Researchers at Lumen Bioscience have pioneered genetic engineering methods to highly express bioactive proteins in spirulina using large-scale cultivation and processing methods appropriate for biopharmaceutical manufacturing.
-
03.03.2022 | Spexis achieves first CARB-X milestone for its thanatin derivatives program and receives funding of up to USD 1.9 million to initiate lead optimization
BIOSPACE | Spexis has received this award based upon the achievement of technical milestones within the previously announced CARB-X collaboration for this program. The award will support the continuation of the "thanatin derivatives program" belonging to Spexis' novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class of antibiotics to potentially treat life-threatening infections caused by difficult-to-treat Gram-negative bacteria.
-
03.02.2022 | Combating AMR with Diagnostics
BIOSPECTRUM | Early diagnosis plays a significant role in effective management of AMR. Faster and accurate diagnostic tests enable identification and pathogen identification so patients can be treated with the most appropriate drug quickly. This prevents antibiotic misuse and overuse, and can play a vital role in timely interventions to improve patient outcomes and reduce the spread of resistance.
-
02.28.2022 | The Global Burden of AMR
INFECTIOUS CONVERSATIONS PODCAST | Episode 1 features Kevin Outterson (CARB-X), Dr. Helen Boucher (Tufts University School of Medicine), and Mary Booth Dwight (Cystic Fibrosis Foundation) who discuss the global burden of AMR.
-
02.17.2022 | Report highlights ‘fragile and failing’ antibiotic pipeline
CIDRAP | The report on antibacterial innovation from the Biotechnology Innovation Organization (BIO) concludes that the breadth and the novelty of the clinical antibacterial pipeline is insufficient to meet the growing threat of antibiotic-resistant pathogens.
-
02.16.2022 | The hidden epidemic
VOX | Antibiotic resistance is approaching a crisis point, and the world needs to act
-
02.05.2022 | Antibiotic Resistant Bacteria, A Growing Global Threat
HealthCall LIVE | Lee Kelso talks with Kevin Outterson from CARB-X about the risk of bacteria that antibiotics can’t kill and the search for effective drugs.
-
02.01.2022 | AMR Action Fund Appoints Scientific Advisory Board
AMR ACTION FUND | Members will play a vital role in evaluating potential investments into clinical-stage companies developing urgently needed antibiotics
-
01.27.2022 | The World’s Next Big Health Emergency Is Already Here
BLOOMBERG OPINION | Covid-19 has claimed nearly 6 million lives. Antimicrobial resistance may claim 10 million annually by 2050 — and that figure is starting to look low.
-
01.27.2022 | AMR Action Fund head aims to boost innovation, funds for new antibiotics
CIDRAP | The science is not the issue, experts say. The big problem is the lack of a viable market for new antibiotics, one that reimburses antibiotic developers for the public health value of their product.
-
01.27.2022 | RTP’s Locus Biosciences grows as it tackles issue of drug-resistant bacteria
THE NEWS & OBSERVER | Locus Biosciences is expecting more growth in 2022, as the gene-editing company strives to provide alternatives to the pressing issue of drug-resistant bacteria.
-
01.26.2022 | Drug-Resistant Superbugs Are Causing More Deaths: What’s Being Done?
HEALTHLINE | For years, scientists have been sounding the alarm about how so-called superbugs can be life threatening. Now, a new study outlines just how life threatening that drug resistance is when it comes to antibiotics, or what scientists call antimicrobial resistance.
-
01.24.2022 | AMR May Be the ‘Next Pandemic’
MEDPAGE TODAY | Feds lead investment in antimicrobial resistance, but more private help is needed, BARDA says
Toggle navigation